Wednesday, December 3 | 8:50 a.m.-9:00 a.m. | W1-SSNMMI05-6 | S405
Reliable standards are still lacking in gallium-68 (Ga-68) DOTATOC PET/CT imaging of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). In this session, a study suggests that criteria named SSTR-RADS 1.0 could fit the bill.
Marta Vaillant, MD, of Hospital Clínico San Carlos in Madrid, Spain, will present an analysis of 77 patients (age range, 25 to 87) with suspected or diagnosed GEP-NET who underwent Ga-68 DOTATOC PET-CT between August 2019 and December 2023. Two nuclear medicine physicians with more than 15 years of experience interpreted the scans using SSTR-RADS 1.0, which includes five categories based on severity (SSTR-RADS-1 to SSTR-RADS-5).
Sixty-six patients had GEP-NETs: 47 with grade 1, 17 with grade 2, and two with grade 3 disease. The most common metastatic sites were regional lymph nodes (28.6%) and liver (29.9%). A strong association was found between SSTR-RADS 1.0 classification and GEP-NET diagnosis (χ² = 58.6, p-value < 0.001), according to the researchers. Logistic regression showed a capacity for correct SSTR-RADS classification in 85.7% of cases.
“By applying the SSTR-RADS 1.0 criteria, the study contributes to reducing interobserver variability, enhancing diagnostic accuracy, and improving communication among multidisciplinary teams,” Vaillant and colleagues wrote.
Ultimately, such improvements are critical for appropriate patient management and therapy selection, particularly regarding peptide receptor radionuclide therapy, they concluded.
Check out this Wednesday morning session to learn all the details.
